These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 22064071)

  • 1. Endogenous secretory receptor for advanced glycation end-products inhibits amyloid-β1-42 uptake into mouse brain.
    Sugihara T; Munesue S; Yamamoto Y; Sakurai S; Akhter N; Kitamura Y; Shiba K; Watanabe T; Yonekura H; Hayashi Y; Hamada J; Yamamoto H
    J Alzheimers Dis; 2012; 28(3):709-20. PubMed ID: 22064071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of mouse orthologue of endogenous secretory receptor for advanced glycation end-products: structure, function and expression.
    Harashima A; Yamamoto Y; Cheng C; Tsuneyama K; Myint KM; Takeuchi A; Yoshimura K; Li H; Watanabe T; Takasawa S; Okamoto H; Yonekura H; Yamamoto H
    Biochem J; 2006 May; 396(1):109-15. PubMed ID: 16503878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAGE regulates BACE1 and Abeta generation via NFAT1 activation in Alzheimer's disease animal model.
    Cho HJ; Son SM; Jin SM; Hong HS; Shin DH; Kim SJ; Huh K; Mook-Jung I
    FASEB J; 2009 Aug; 23(8):2639-49. PubMed ID: 19332646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor for advanced glycation end products is a promising target of diabetic nephropathy.
    Yamamoto Y; Doi T; Kato I; Shinohara H; Sakurai S; Yonekura H; Watanabe T; Myint KM; Harashima A; Takeuchi M; Takasawa S; Okamoto H; Hashimoto N; Asano M; Yamamoto H
    Ann N Y Acad Sci; 2005 Jun; 1043():562-6. PubMed ID: 16037279
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RAGE does not affect amyloid pathology in transgenic ArcAbeta mice.
    Vodopivec I; Galichet A; Knobloch M; Bierhaus A; Heizmann CW; Nitsch RM
    Neurodegener Dis; 2009; 6(5-6):270-80. PubMed ID: 20145420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAGE mediates vascular injury and inflammation after global cerebral ischemia.
    Kamide T; Kitao Y; Takeichi T; Okada A; Mohri H; Schmidt AM; Kawano T; Munesue S; Yamamoto Y; Yamamoto H; Hamada J; Hori O
    Neurochem Int; 2012 Feb; 60(3):220-8. PubMed ID: 22202666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endogenous secretory receptor for advanced glycation end-products and cardiovascular disease in end-stage renal disease.
    Nishizawa Y; Koyama H
    J Ren Nutr; 2008 Jan; 18(1):76-82. PubMed ID: 18089449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Method for measurement of the blood-brain barrier permeability in the perfused mouse brain: application to amyloid-beta peptide in wild type and Alzheimer's Tg2576 mice.
    LaRue B; Hogg E; Sagare A; Jovanovic S; Maness L; Maurer C; Deane R; Zlokovic BV
    J Neurosci Methods; 2004 Sep; 138(1-2):233-42. PubMed ID: 15325132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of an ELISA for esRAGE and its application to type 1 diabetic patients.
    Sakurai S; Yamamoto Y; Tamei H; Matsuki H; Obata K; Hui L; Miura J; Osawa M; Uchigata Y; Iwamoto Y; Watanabe T; Yonekura H; Yamamoto H
    Diabetes Res Clin Pract; 2006 Aug; 73(2):158-65. PubMed ID: 16488505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer.
    Mackic JB; Stins M; McComb JG; Calero M; Ghiso J; Kim KS; Yan SD; Stern D; Schmidt AM; Frangione B; Zlokovic BV
    J Clin Invest; 1998 Aug; 102(4):734-43. PubMed ID: 9710442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monomeric Aβ1-42 and RAGE: key players in neuronal differentiation.
    Piras S; Furfaro AL; Piccini A; Passalacqua M; Borghi R; Carminati E; Parodi A; Colombo L; Salmona M; Pronzato MA; Marinari UM; Tabaton M; Nitti M
    Neurobiol Aging; 2014 Jun; 35(6):1301-8. PubMed ID: 24484607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apical-to-basolateral transport of amyloid-β peptides through blood-brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by P-glycoprotein.
    Candela P; Gosselet F; Saint-Pol J; Sevin E; Boucau MC; Boulanger E; Cecchelli R; Fenart L
    J Alzheimers Dis; 2010; 22(3):849-59. PubMed ID: 20858979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of RAGE splicing by hnRNP A1 and Tra2β-1 and its potential role in AD pathogenesis.
    Liu XY; Li HL; Su JB; Ding FH; Zhao JJ; Chai F; Li YX; Cui SC; Sun FY; Wu ZY; Xu P; Chen XH
    J Neurochem; 2015 Apr; 133(2):187-98. PubMed ID: 25689357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
    Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
    J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective Effects of Endogenous Secretory Receptor for Advanced Glycation End-products in Brain Ischemia.
    Shimizu Y; Harashima A; Munesue S; Oishi M; Hattori T; Hori O; Kitao Y; Yamamoto H; Leerach N; Nakada M; Yamamoto Y; Hayashi Y
    Aging Dis; 2020 May; 11(3):547-558. PubMed ID: 32489701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of formyl peptide receptors in receptor for advanced glycation end products (RAGE)--and amyloid beta 1-42-induced signal transduction in glial cells.
    Slowik A; Merres J; Elfgen A; Jansen S; Mohr F; Wruck CJ; Pufe T; Brandenburg LO
    Mol Neurodegener; 2012 Nov; 7():55. PubMed ID: 23164356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain.
    Deane R; Du Yan S; Submamaryan RK; LaRue B; Jovanovic S; Hogg E; Welch D; Manness L; Lin C; Yu J; Zhu H; Ghiso J; Frangione B; Stern A; Schmidt AM; Armstrong DL; Arnold B; Liliensiek B; Nawroth P; Hofman F; Kindy M; Stern D; Zlokovic B
    Nat Med; 2003 Jul; 9(7):907-13. PubMed ID: 12808450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury.
    Yonekura H; Yamamoto Y; Sakurai S; Petrova RG; Abedin MJ; Li H; Yasui K; Takeuchi M; Makita Z; Takasawa S; Okamoto H; Watanabe T; Yamamoto H
    Biochem J; 2003 Mar; 370(Pt 3):1097-109. PubMed ID: 12495433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products.
    Kaji Y; Usui T; Ishida S; Yamashiro K; Moore TC; Moore J; Yamamoto Y; Yamamoto H; Adamis AP
    Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):858-65. PubMed ID: 17251488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of alternative splicing of the receptor for advanced glycation endproducts (RAGE) through G-rich cis-elements and heterogenous nuclear ribonucleoprotein H.
    Ohe K; Watanabe T; Harada S; Munesue S; Yamamoto Y; Yonekura H; Yamamoto H
    J Biochem; 2010 May; 147(5):651-9. PubMed ID: 20028692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.